Activity and safety of palbociclib in ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Activity and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: a biomarker-driven phase 2 study
Author(s) :
Toulmonde, Maud [Auteur]
Bellera, Carine A. [Auteur]
Blay, Jean-Yves [Auteur]
Bouche, Olivier [Auteur]
Mir, Olivier [Auteur]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Isambert, Nicolas [Auteur]
Duffaud, Florence [Auteur]
Esnaud, Thomas [Auteur]
Boidot, Romain [Auteur]
Geneste, Damien [Auteur]
Ghiringhelli, François [Auteur]
Lucchesi, Carlo [Auteur]
Le Loarer, François [Auteur]
Italiano, Antoine [Auteur]
Bellera, Carine A. [Auteur]
Blay, Jean-Yves [Auteur]
Bouche, Olivier [Auteur]
Mir, Olivier [Auteur]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Isambert, Nicolas [Auteur]
Duffaud, Florence [Auteur]
Esnaud, Thomas [Auteur]
Boidot, Romain [Auteur]
Geneste, Damien [Auteur]
Ghiringhelli, François [Auteur]
Lucchesi, Carlo [Auteur]
Le Loarer, François [Auteur]
Italiano, Antoine [Auteur]
Journal title :
Clinical cancer research . an official journal of the American Association for Cancer Research
Abbreviated title :
Clin. Cancer Res.
Publication date :
2019-04-12
ISSN :
1078-0432
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
OBJECTIVE: CDKN2A
METHODS: This is a multicenter single-arm phase II clinical trial assessing safety and efficacy of palbociclib in patients with advanced GIST bearing CDKN2ACDKN2A
RESULTS: As of May 2017, 71 patients had ...
Show more >OBJECTIVE: CDKN2A METHODS: This is a multicenter single-arm phase II clinical trial assessing safety and efficacy of palbociclib in patients with advanced GIST bearing CDKN2ACDKN2A RESULTS: As of May 2017, 71 patients had been included in the study, and 29 patients (40.3%) met the molecular eligibility requirement. Twenty-five patients (86.2%) had grade 1-2 adverse events (AEs) and 12 patients (41.4%) grade 3-4 AEs possibly related to the drug. The planned interim statistical analysis performed after central histologic and radiological review showed that 19 (86.4%) out of the first 22 evaluable patients had PD at 4 months. CDKN2ACCNE1CDKN1A/P21LRRC3B CONCLUSIONS: Palbociclib has no significant clinical activity as a single agent in P16/CDKN2A-Show less >
Show more >OBJECTIVE: CDKN2A METHODS: This is a multicenter single-arm phase II clinical trial assessing safety and efficacy of palbociclib in patients with advanced GIST bearing CDKN2ACDKN2A RESULTS: As of May 2017, 71 patients had been included in the study, and 29 patients (40.3%) met the molecular eligibility requirement. Twenty-five patients (86.2%) had grade 1-2 adverse events (AEs) and 12 patients (41.4%) grade 3-4 AEs possibly related to the drug. The planned interim statistical analysis performed after central histologic and radiological review showed that 19 (86.4%) out of the first 22 evaluable patients had PD at 4 months. CDKN2ACCNE1CDKN1A/P21LRRC3B CONCLUSIONS: Palbociclib has no significant clinical activity as a single agent in P16/CDKN2A-Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Université de Lille
Université de Lille
Submission date :
2019-12-09T16:49:44Z